ALZN Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Alzamend Neuro, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.31 |
| 52 Week High | US$15.06 |
| 52 Week Low | US$1.25 |
| Beta | -0.038 |
| 11 Month Change | -18.63% |
| 3 Month Change | -54.04% |
| 1 Year Change | -87.31% |
| 33 Year Change | -99.62% |
| 5 Year Change | n/a |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?
Jul 26
Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?
Mar 20We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate
Oct 14Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial
Oct 05Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia
Sep 29Alzamend Neuro receives positive pre-IND response from FDA for AL001
Jul 18Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market
Dec 18Alzamend Neuro closes $14.4M IPO
Jun 17Shareholder Returns
| ALZN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.7% | 2.5% | 2.2% |
| 1Y | -87.3% | 16.1% | 31.6% |
Return vs Industry: ALZN underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: ALZN underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| ALZN volatility | |
|---|---|
| ALZN Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALZN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALZN's weekly volatility has decreased from 30% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 6 | Stephan Jackman | www.alzamend.com |
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001.
Alzamend Neuro, Inc. Fundamentals Summary
| ALZN fundamental statistics | |
|---|---|
| Market cap | US$5.86m |
| Earnings (TTM) | -US$7.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs ALZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALZN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.39m |
| Earnings | -US$7.39m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALZN perform over the long term?
See historical performance and comparison